Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability,
bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or
0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.